Brad Hoffman, Ph.D.

Brad HoffmanDivision

Cellular and Molecular Therapy

Academic Title

Assistant Professor

Contact Information

352-273-8152 (phone)
352-273-8342 (fax)


Dr. Hoffman is a cellular immunologist with a major interest in immune modulation and tolerance induction using adeno-associated virus (AAV) gene therapy. Dr. Hoffman earned his Ph.D. in Immunology from Temple University School of Medicine in 2006. He subsequently performed postdoctoral research in gene therapy at University of Florida.  In 2010, he received the Kokomoor Award for Excellence in Pediatric Research and became an Assistant Professor of Pediatrics in the Division of Cellular & Molecular Therapy. Dr. Hoffman’s research has earned him multiple awards and grants, including an American Heart Association Fellowship (2007), Pfizer Award in Hemophilia Research (ASPIRE, 2011), BD Bioscience Immunology Award (2011), Children’s Miracle Network grant (2012-13), National Multiple Sclerosis Society Pilot grant (2014), and research grant (2015). He is also a NIH – Pediatric Research LRP Recipient (2012-14).


  • Postdoctoral Training, University of Florida, College of Medicine
  • Ph.D. – Microbiology and Immunology, Temple University, School of Medicine
  • B.S. – Chemistry & Biology , University of Central Florida

Research Overview

My research group is particularly interested in the mechanisms surrounding the generation of antigen-specific regulatory T-cells (Tregs), and the role they have in tolerance induction following gene transfer. Our major focus is aimed at exploiting the unique molecular and cellular mechanisms of liver-directed AAV gene therapy in order to re-establish immunological self-tolerance to a protein through the induction and expansion of antigen-specific regulatory T-cells. Through an innovative strategy, our group seeks to develop a clinically relevant therapy that will abrogate the progression of autoimmune neurological diseases such as Multiple Sclerosis.

Key Publications

View a complete list of publications on PubMed

  • Hoffman, B. E., Zolotukhin, I., Herzog, R. W., and Cao, O. Capsid Modified AAV2 Vectors Are Capable of Generating Functional Cytotoxic T Cells in a Prime-Boost Vaccine Protocol, Molecular Therapy (2013) 21, S74-S75.
  • Zolotukhin, I., Luo, D., Gorbatyuk, O. S., Hoffman, B. E., Warrington Jr, K. H., and Coa, O. Improved Adeno-associated Viral Gene Transfer to Murine Glioma, Journal of Genetic Syndromes & Gene Therapy (2013) 04.
  • Hoffman, B. E. & Herzog, R. W. Covert warfare against the immune system: decoy capsids, stealth genomes, and suppressors. Molecular therapy : the journal of the American Society of Gene Therapy 21, 1648-1650, (2013).
  • Markusic, D. M., Hoffman, B. E., Perrin, G. Q., Nayak, S., Wang, X., LoDuca, P. A., High, K. A., and Herzog, R. W. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies, EMBO Molecular Medicine (2013), 1-12.
  • Hoffman, B. E., Zolotukhin, I., Herzog, R. W., and Cao, O. Capsid Modified AAV2 Vectors Are Capable of Generating Vaccine-Mediated Protection, Molecular Therapy (2012) 20, S257-S258.
  • Nayak, S., Sarkar, D., Perrin, G. Q., Moghimi, B., Hoffman, B. E., Zhou, S., Byrne, B. J., and Herzog, R. W. Prevention and Reversal of Antibody Responses Against Factor IX in Gene Therapy for Hemophilia B, Frontiers in microbiology (2011) 2, 244.
  • Hoffman, B. E., Martino, A. T., Sack, B. K., Cao, O., Liao, G., Terhorst, C., and Herzog, R. W. Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer, Molecular therapy : the journal of the American Society of Gene Therapy (2011) 19, 1263-1272.
  • Verma, D., Moghimi, B., LoDuca, P. A., Singh, H. D., Hoffman, B. E., Herzog, R. W., and Daniell, H. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice, Proceedings of the National Academy of Sciences of the United States of America (2010) 107, 7101-7106.
  • Hoffman, B. E., Cao, O., Moghimi, B., Nayak, S., Cooper, M., Zhou, S., Ertl, H. C., High, K. A., and Herzog, R. W. Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B, Molecular therapy : the journal of the American Society of Gene Therapy (2009) 17, 1733-1742.
  • Cooper, M., Nayak, S., Hoffman, B. E., Terhorst, C., Cao, O., and Herzog, R. W. Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer, Human gene therapy (2009) 20, 767-776.
  • Hoffman, B. E., Dobrzynski, E., Wang, L., Hirao, L., Mingozzi, F., Cao, O., and Herzog, R. W. Muscle as a target for supplementary factor IX gene transfer, Human gene therapy (2007) 18, 603-613.
  • Hoffman, B., and Herzog, R. Initial identification of a mouse human factor IX-Specific CD8+ T-Cell epitope., Blood (2006) 108, 469B-469B.
  • Hoffman, B., Chang, J., Katsetos, C., Platsoucas, C., and Oleszak, E. T cells infiltrating the CNS of Theiler’s virus (TMEV)-infected mice during late chronic demyelinating disease are G0/G1 arrested and do not undergo apoptosis, Journal of Neuroimmunology (2004) 154, 204-204.
  • Prineas, J. W., Kwon, E. E., Cho, E. S., Sharer, L. R., Barnett, M. H., Oleszak, E. L., Hoffman, B. E., and Morgan, B. P. Immunopathology of secondary-progressive multiple sclerosis, Annals of neurology (2001) 50, 646-657.